Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluvoxamine maleate, quantity: 100 mg - tablet, film coated - excipient ingredients: titanium dioxide; mannitol; macrogol 8000; magnesium stearate; hyetellose; iron oxide red; iron oxide yellow; iron oxide black - indicated for the treatment of major depression in adults. indicated for the treatment of obsessive compulsive disorder in children aged 8 years of age and older, adolescents, and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluvoxamine maleate, quantity: 50 mg - tablet, film coated - excipient ingredients: titanium dioxide; macrogol 8000; magnesium stearate; mannitol; hyetellose; iron oxide yellow - indicated for the treatment of major depression in adults. indicated for the treatment of obsessive compulsive disorder in children aged 8 years of age and older, adolescents, and adults.

United States - English - NLM (National Library of Medicine)

caraco pharmaceutical laboratories, ltd. - fluvoxamine maleate (unii: 5lgn83g74v) (fluvoxamine - unii:o4l1xpo44w) - fluvoxamine maleate 25 mg - fluvoxamine maleate tablets, usp are indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (ocd), as defined in dsm-iii-r or dsm-iv. the obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. obsessive compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. the efficacy of fluvoxamine maleate tablets, usp was established in three trials in outpatients with ocd: two 10-week trials in adults, one 10-week trial in pediatric patients (ages 8-17). (see clinical studies [14].) coadministration of tizanidine, thioridazine, alosetron, or pimozide with fluvoxamine maleate tablets is contraindicated. (see warnings and precautions [5.4-5.7].) the use of maois concomitantly wit

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - fluvoxamine maleate -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - fluvoxamine maleate -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - fluvoxamine maleate -

United States - English - NLM (National Library of Medicine)

torrent pharmaceuticals limited - fluvoxamine maleate (unii: 5lgn83g74v) (fluvoxamine - unii:o4l1xpo44w) - fluvoxamine maleate 100 mg - fluvoxamine maleate extended-release capsules are indicated for the treatment of obsessive compulsive disorder (ocd), as defined in the dsm-iv. obsessive compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. the obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning.  the efficacy of fluvoxamine maleate extended-release capsules was demonstrated in one 12-week trial in adults with fluvoxamine maleate extended-release capsules as well as in two 10-week trials in adults and in one 10-week trial in children and adolescents (ages 8 to 17 years) with immediate-release fluvoxamine tablets in outpatients with the diagnosis of ocd as defined in dsm-iv or dsm-iii-r (see clinical studies  [14.1, 14.3] ). the efficacy of fluv

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - fluvoxamine maleate (unii: 5lgn83g74v) (fluvoxamine - unii:o4l1xpo44w) - fluvoxamine maleate 50 mg - fluvoxamine maleate tablets usp are indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (ocd), as defined in dsm-iii-r or dsm-iv. the obsessions or compulsions cause marked distress, are time-consuming or significantly interfere with social or occupational functioning. obsessive compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses or images (obsessions) that are ego-dystonic and/or repetitive, purposeful and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. the efficacy of fluvoxamine maleate tablets usp was established in three trials in outpatients with ocd: two 10-week trials in adults, one 10-week trial in pediatric patients (ages 8 to 17) (see 14 clinical studies ). co-administration of tizanidine, thioridazine, alosetron or pimozide with fluvoxamine maleate is contraindicated (see warnings and precautions, 5.4 potential thioridazine interaction, 5.5 potential tizan

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - fluvoxamine maleate (unii: 5lgn83g74v) (fluvoxamine - unii:o4l1xpo44w) - fluvoxamine maleate 25 mg - fluvoxamine maleate tablets are indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (ocd), as defined in dsm-iii-r or dsm-iv. the obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. obsessive compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. the efficacy of fluvoxamine maleate tablets was established in four trials in outpatients with ocd: two 10-week trials in adults, one 10-week trial in pediatric patients (ages 8-17), and one maintenance trial in adults [see clinical studies (14)]. [see warnings and precautions (5.4 to 5.7).] the use of maois intended to treat psychiatric disorders with fluvoxamine maleate tablets or within 14 days of stopping treatment

United States - English - NLM (National Library of Medicine)

eon labs, inc. - fluvoxamine maleate (unii: 5lgn83g74v) (fluvoxamine - unii:o4l1xpo44w) - fluvoxamine maleate 25 mg - fluvoxamine maleate tablets, usp are indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (ocd), as defined in dsm-iii-r or dsm-iv. the obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. obsessive compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. the efficacy of fluvoxamine maleate tablets, usp was established in four trials in outpatients with ocd: two 10-week trials in adults, one 10-week trial in pediatric patients (ages 8 to 17), and one maintenance trial in adults (see clinical studies [14] ). ( see warnings and precautions [5.4 to 5.7]). the use of maois intended to treat psychiatric disorders with fluvoxamine maleate or within 14 days of stopping tr